
Give specialists a clearer view of the organisational question.
An antimicrobial stewardship team needs information that supports careful review under real service pressures. More charts do not automatically create more useful decisions. Our proposed PHARMORIS evaluation concerns the preparation of an organisational stewardship brief for a defined question, such as the completeness of a review process or the implementation of an agreed policy. It would support source checking and coordination while keeping diagnosis, prescribing and clinical interpretation with qualified professionals. The incentive is a more usable review, not indiscriminate reduction of antimicrobial use.
In development · Intended scope and questions for evaluation
The organisation.
The people around it.
A formulary implementation or discharge programme can change work inside a hospital and in the services receiving its patients.
The people involved
Chief pharmacists, clinical directors, medicines optimisation teams, operations, procurement and finance.
The dependencies
Specialist teams, general practice, community pharmacy, procurement, commissioners, digital and information-governance colleagues.
What to examine
Clinical applicability, staff capacity, implementation effort, continuity of care and full programme cost.
An illustrative set of programme relationships. The actual participants, authority, funding and permissions must be established for the defined setting. Explore every organisation perspective.
Begin with the purpose of the programme.
NICE's stewardship guidance and the UKHSA Start smart then focus toolkit provide the national context (NICE, n.d.; UKHSA, n.d.). A local evaluation should state what the team wants to improve and why the selected information is relevant. The scope might concern whether an agreed review is documented and how outstanding work is escalated. It should not assume that fewer prescriptions or a lower purchasing cost is always better care. The organisational question needs clinical ownership so a convenient measure cannot quietly become the purpose of the programme.
Use a denominator that means something.
Activity changes can reflect case mix, admissions, service reconfiguration, recording or supply. The proposed analysis would establish which of these can be examined and which remain unknown. Define the population, period and unit before displaying a trend. Compare like with like where possible and label gaps clearly. A source-linked brief should help reviewers question an apparent change rather than imply that a line moving down proves better stewardship. The evidence needed to explain the trend may be different from the evidence that first reveals it.
A process-review measure might examine documented reviews among the locally defined episodes due for review, rather than using all prescriptions as the denominator. Missing documentation and a documented decision not to change treatment should remain different observations. The responsible specialists must define the criterion and interpret it. This is a way to make an organisational audit question explicit, not a software rule for determining whether an individual antimicrobial course should continue or stop.
Keep recommendations distinct from observations.
A recorded process measure, a specialist interpretation and a proposed improvement should be presented separately. This lets the reviewer see which statements follow directly from the information and which require professional judgement. A preparation tool should not turn incomplete organisational data into patient-specific treatment advice. The proposed brief would also identify where a source or local policy has changed. Maintaining that distinction is central to commercial usefulness: a faster draft is valuable only if specialists can understand and challenge its reasoning.
Test one bounded review task.
A first PHARMORIS evaluation could use public guidance, approved local process documents and synthetic or appropriately aggregated examples. Compare preparation of a stewardship review brief with the existing audit or meeting pack. Specialists would define critical facts, missing information and unacceptable inferences before assessing the outputs. The initial scope would exclude live clinical recommendations and changes to prescribing systems. It would test preparation quality and effort, while preserving the team's established audit, clinical governance and escalation responsibilities.
Measure the review that professionals have to do.
Potential outcomes include important context correctly represented, denominator errors, unsupported conclusions, source traceability and total preparation plus checking time. Include examples where the information is incomplete or where a trend has several plausible explanations. A useful output may be a better question for further investigation rather than an immediate action. Any later claim about prescribing quality, resistance or patient outcomes would require a suitable study and specialist interpretation. Those results cannot be inferred from the quality of a draft organisational brief.
Stop when a metric becomes an unsafe instruction.
Stop if the draft suggests that an individual treatment should change, omits relevant context or treats a crude reduction in use as a clinical benefit. Agree tolerances for correction burden and incomplete source coverage in advance. If the evaluation shows that the team already prepares the material efficiently, a new tool may add little value. A credible commercial proposition must accept that possibility. The result should guide investment towards an actual preparation problem rather than create demand by criticising work that already functions well.
Bring the next stewardship meeting question.
An antimicrobial pharmacist, clinical lead and audit representative can define a recurring review task and the standards its output must meet. We can discuss whether a focused comparison is feasible with permitted material. PHARMORIS remains in development; this page describes a proposed organisational application, not a clinical prescribing product or a demonstrated stewardship outcome. The potential value is time and attention directed towards a more inspectable review, with a clear decision about whether further evidence and development are justified.
Sources and further reading
NICE (n.d.) Antimicrobial stewardship, NG15. Available at: https://www.nice.org.uk/guidance/ng15 (Accessed: 14 October 2026).
UKHSA (n.d.) Start smart then focus toolkit. Available at: https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus/start-smart-then-focus-antimicrobial-stewardship-toolkit-for-inpatient-care-settings (Accessed: 14 October 2026).
Bring the question
your organisation
needs to move.
Tell us where the programme gets stuck, who is affected and what a worthwhile evaluation would help you decide.
Discuss a PHARMORIS evaluationAn initial conversation should describe the organisational question. Agree the purpose and information requirements before sharing records.